Wet Age Related Macular Degeneration clinical trials

Explore recruiting wet age related macular degeneration clinical trials.

Recruiting wet age related macular degeneration studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Wet Age Related Macular Degeneration trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

The Sahlgrenska Anti-VEGF (SAHLVE) Study - a Prospective Randomized Double-blind Comparison of Bevacizumab and Aflibercept in Patients With Neovascular Age-related Macular Degeneration

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD (EYP-1901-302)

Germany, Czechia, Hungary, Poland, Slovakia

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Parallel Group, Multicenter Study to Compare Efficacy, Safety, Pharmacokinetics, and Immunogenicity of BP05 Versus EU-Approved Lucentis® in Patients with Wet (Neovascular) Age-Related Macular Degeneration

Slovakia, Latvia

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase IIIb, Global, Multicenter, Randomized, Visual Assessor−Masked Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration (Velodrome)

Austria, Italy, Belgium, Spain, France, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Wet Age Related Macular Degeneration trials by city

Wet Age Related Macular Degeneration clinical trials

Recruiting wet age related macular degeneration studies right now

Stem Cell Ophthalmology Treatment Study II

Acute Intra Ocular Pressure Monitoring After Aflibercept 8mg/0.07mL

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD)

Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

A Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD)

Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals

Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration

Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)

A Clinical Study Evaluating the Safety and Efficacy of SKG0106 in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Also recruiting in Europe

The Sahlgrenska Anti-VEGF (SAHLVE) Study - a Prospective Randomized Double-blind Comparison of Bevacizumab and Aflibercept in Patients With Neovascular Age-related Macular Degeneration

A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD (EYP-1901-302)

A Phase 3, Randomized, Double-Blind, Parallel Group, Multicenter Study to Compare Efficacy, Safety, Pharmacokinetics, and Immunogenicity of BP05 Versus EU-Approved Lucentis® in Patients with Wet (Neovascular) Age-Related Macular Degeneration

A Phase IIIb, Global, Multicenter, Randomized, Visual Assessor−Masked Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration (Velodrome)

Wet Age Related Macular Degeneration trials by city

Other conditions